IPO round-up: Histogenics, Great Basin try their luck
This article was originally published in Clinica
Executive Summary
Another day sees two more medtech firms hoping to go public: regenerative medicine specialist Histogenics, which is targeting $65m; and molecular diagnostics firm Great Basin, which has priced a more modest $8m IPO.